Identifying safety signals during discovery efficacy testing

August 14, 2018 - Less than a minute read

In conjunction with Novartis

With the cost for drug development soaring to an estimated $2.9 billion dollars, there is an increasing shift towards the quick win, fast failure drug development paradigm in which the goal is to reduce attrition during the costly late-stage of the development pipeline [1]. Preclinical animal testing provides data on both the safety and potential efficacy of compounds prior to receiving approval for human clinical trials. ETC…

Our study was designed to examine efficacy of a compound in a respiratory disease model. While the goal was to demonstrate that elevated breathing rates were reduced following administration of the compound, we potential safety signal appeared in motion data. ETC….